Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly, committed to reducing cardiovascular risk and making a meaningful impact on patients’ lives. UK-NP-00132 April 2022
Address
c/o TMF Group 20 Farringdon StreetLondon
EC4A 4AB
United Kingdom